In a highly-anticipated world-first, the Texas Heart Institute has successfully implanted an artificial titanium heart that uses the same technology as bullet trains to pump blood mechanically throughout the body.
Called the Total Artificial Heart (TAH), the feat is seen as a major step in keeping people alive for longer and longer periods while they wait for heart transplants.
Texas Heart partnered with the medical tech company BiVACOR to create the TAH. It’s a titanium-constructed biventricular rotary blood pump with a single moving part that utilizes a magnetically levitated rotor that pumps the blood and replaces both ventricles of a failing heart.
The benefit of using magnetic levitation is that none of the moving parts ever scrape or slide against each other, reducing friction, and dramatically increasing the longevity of the device. But what’s really cool is the TAH can pump blood at a rate of 12 liters per minute, enough to allow an adult male to engage in exercise.
The first-in-human clinical study, overseen closely by the FDA, aims to evaluate the safety and performance of the BiVACOR TAH as a bridge-to-transplant solution for patients with severe bi or univentricular heart failure. Following this first implantation completed at Baylor St. Luke’s Medical Center in the Texas Medical Center, four additional patients are to be enrolled in the study.
“The Texas Heart Institute is enthused about the groundbreaking first implantation of BiVACOR’s TAH. With heart failure remaining a leading cause of mortality globally, the BiVACOR TAH offers a beacon of hope for countless patients awaiting a heart transplant,” said Dr. Joseph Rogers, President and Chief Executive Officer of The Texas Heart Institute and National Principal Investigator on the research.
REDUCING HEART FAILURE: New Pacemaker Developed that Uses the Heartbeat to Recharge its Battery
“We are proud to be at the forefront of this medical breakthrough, working alongside the dedicated teams at BiVACOR, Baylor College of Medicine, and Baylor St. Luke’s Medical Center to transform the future of heart failure therapy for this vulnerable population.”
Heart failure is a global epidemic affecting at least 26 million people worldwide, 6.2 million adults in the US, and is increasing in prevalence. Heart transplantations are reserved for those with severe heart failure and are limited to fewer than 6,000 procedures per year globally. Consequently, the US National Institutes of Health estimated that up to 100,000 patients could immediately benefit from mechanical alternatives.
TRANSPLANT DEVELOPMENTS: New Tech Revives ‘Unusable’ Organs–10 Successful Transplants Used Kidneys That Are Normally Discarded
The successful implantation of BiVACOR’s TAH highlights the potential of innovative technologies to address critical challenges in cardiac care, such as long transplantation waitlists.
“This achievement would not have been possible without the courage of our first patient and their family, the dedication of our team, and our expert collaborators at The Texas Heart Institute,” said Daniel Timms, founder and CTO of BiVACOR.
WATCH the story below…
SHARE This Groundbreaking First Step On A Journey Towards Better Transplant Science…
Scary, but good.